CytomX Therapeutics Inc
NASDAQ:CTMX 4:00:00 PM EDT
| Market Cap (Intraday) | 112.78M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.95 |
| 50-Day MA | $2.02 |
| 200-Day MA | $1.61 |
CytomX Therapeutics Inc Stock, NASDAQ:CTMX
151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080-1913
United States of America
Phone: +1.605.515.3185
Number of Employees: 122
Description
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.